Smith & Wesson Brands (SWBI) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
17 Jun, 2026Executive summary
Q4 net sales reached $178.4 million, up 26.7% year-over-year, with full-year net sales at $523.8 million, a 10.4% increase over the prior year.
Q4 and full fiscal 2026 results exceeded expectations, driven by strong consumer demand, innovation, and operational execution.
Q4 GAAP net income was $16.2 million ($0.36/share), nearly doubling from $8.6 million ($0.19/share) last year.
Outperformance driven by strong handgun shipments, with new products accounting for 38% of shipments in Q4 and the full year.
Cash from operations in Q4 was $74.6 million; full-year operating cash flow was $114.2 million.
Financial highlights
Q4 non-GAAP net income was $16.2 million ($0.36/share), up from $9.0 million ($0.20/share) last year.
Q4 Adjusted EBITDAS was $30.9 million (17.3% margin), up from $23.5 million (16.7%) last year.
Gross margin improved to 29.8%, up one percentage point, aided by higher production volume and a 2%-3% price increase.
Debt reduced to $20 million from $80 million at prior year-end.
Dividends paid totaled $23.2 million; $60 million repaid on revolving credit facility.
Outlook and guidance
Fiscal 2027 revenue expected to grow mid-single digits over fiscal 2026, with Q1 revenues projected 15%-20% higher year-over-year.
Margins in Q1 anticipated to be one to two points higher, despite a sequential 5% decline in ASPs due to product mix.
Operating expenses for Q1 expected to rise about 20% year-over-year due to higher volume and profit-related costs.
Effective tax rate for fiscal 2027 projected at 30%.
Industry demand expected to remain robust in fiscal 2027.
Latest events from Smith & Wesson Brands
- Q3 net sales up 17.1% to $135.7M, with higher margins and strong Q4 outlook.SWBI
Q3 20265 Mar 2026 - Double-digit growth in revenue and net income, with 2025 outlook for continued gains and higher dividends.SWBI
Q4 20243 Feb 2026 - Q1 sales fell 22.7%, but new products and margin gains support a positive full-year outlook.SWBI
Q1 202522 Jan 2026 - Board re-elections, executive pay approval, and strong financial growth highlighted the meeting.SWBI
AGM 202420 Jan 2026 - Q2 sales up 3.8% to $129.7M, but guidance cut as inflation softens demand and margins.SWBI
Q2 202511 Jan 2026 - Q3 sales fell 15.7% as new products drove 41% of revenue, but margins and sales remain pressured.SWBI
Q3 202527 Dec 2025 - Q2 sales dipped 3.9% but cash flow and new product momentum support a strong Q3 outlook.SWBI
Q2 20267 Dec 2025 - Director elections, say-on-pay, and a human rights proposal headline a governance-focused agenda.SWBI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor ratification, all board-backed.SWBI
Proxy Filing1 Dec 2025